Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Biovitrum and Symphogen initiate clinical study of RhD polyclonal antibody Sym-001

April 17, 2008

AnGes launches Naglazyme for mucopolysaccharidosis VI in Japan

April 16, 2008

Novel oral calcium receptor antagonists demonstrate bone formation activity in initial studies

April 16, 2008

Medgenics to initiate phase I/II clinical trials in Israel of Epodure in anemia

April 16, 2008

Isis reports additional results from phase II study of mipomersen in familial hypercholesterolemia

April 16, 2008

Oramed initiates phase IIa clinical trial for oral insulin

April 15, 2008

AtheroGenics reports interim results from phase III AGI-1067 diabetes trial

April 15, 2008

Symbollon reports results of IoGen phase III trial in fibrocystic breast-related pain

April 15, 2008

Glucose-lowering activity of Merck's novel glucagon receptor antagonist shown in vivo

April 14, 2008

Recent patents disclose novel antidiabetic agents

April 11, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...